A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DEDN6526A in Patients With Metastatic or Unresectable Melanoma
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2015
At a glance
- Drugs RG 7636 (Primary)
- Indications Malignant melanoma; Uveal melanoma
- Focus Adverse reactions
- Sponsors Genentech
- 01 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 09 Apr 2014 Results presented at the 105th Annual Meeting of the American Association for Cancer Research.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History